<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03463161</url>
  </required_header>
  <id_info>
    <org_study_id>IRB17-1539</org_study_id>
    <nct_id>NCT03463161</nct_id>
  </id_info>
  <brief_title>Epacadostat and Pembrolizumab in Patients With Head and Neck Cancer That Have Failed Prior Immunotherapy</brief_title>
  <acronym>ORKA</acronym>
  <official_title>A Phase II Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to determine response rate of the combination of pembrolizumab plus epacadostat in&#xD;
      patients with head and neck cancers that have received prior immunotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study stopped early due to investigator conflict of interest.&#xD;
  </why_stopped>
  <start_date type="Actual">March 23, 2018</start_date>
  <completion_date type="Actual">December 4, 2018</completion_date>
  <primary_completion_date type="Actual">December 4, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be assigned to one of 2 study groups based on response to prior therapy.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>up to 18 months</time_frame>
    <description>Rate of clinical disease response (tumor shrinkage) as seen on imaging.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>1 year</time_frame>
    <description>Number of patients that have not had disease worsening across both study groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>1 year</time_frame>
    <description>Number of patients surviving across both study groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effects</measure>
    <time_frame>6 months</time_frame>
    <description>Number of patients with side effect. Summary of side effects by type is provided in adverse events section below.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Acquired Resistance Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants that have benefited from prior treatment with immunotherapy. Defined as response to prior treatment and/or stable disease lasting at least 5 months and disease worsening seen on most recent imaging.&#xD;
Participants will receive Pembrolizumab and Epacadostat.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Suboptimal Benefit Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants that have not benefited from prior treatment with immunotherapy. Defined as stable disease lasting at least 5 months or suboptimal response (11-49% shrinkage of tumors). Disease continues to be stable on most recent imaging.&#xD;
Participants will receive Pembrolizumab and Epacadostat.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab (200mg/kg) given by intravenous infusion every 3 weeks.</description>
    <arm_group_label>Acquired Resistance Group</arm_group_label>
    <arm_group_label>Suboptimal Benefit Group</arm_group_label>
    <other_name>Keytruda</other_name>
    <other_name>MK3476</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epacadostat</intervention_name>
    <description>Epacadostat (100mg) taken by mouth twice a day.</description>
    <arm_group_label>Acquired Resistance Group</arm_group_label>
    <arm_group_label>Suboptimal Benefit Group</arm_group_label>
    <other_name>INCB024360</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Squamous cell carcinoma of the head and neck (which cannot be surgically removed and&#xD;
             not amenable to curative intent therapy)&#xD;
&#xD;
          -  Meet criteria for either the Acquired Resistance OR the Suboptimal Benefit Group *&#xD;
             Acquired Resistance defined as (i and ii must both be met): i. Prior benefit from&#xD;
             anti-PD-1/PD-L1 therapy defined as a) prior response, and/or b) ≥5 months of stable&#xD;
             disease (SD). Intervening therapies are allowed.&#xD;
&#xD;
        ii. Progressive Disease (PD) on recent scans&#xD;
&#xD;
        * Suboptimal Benefit is defined as (i and ii must both be met): i. Prolonged stable disease&#xD;
        ≥5 months OR Suboptimal response (&gt;10% &amp; &lt;50% shrinkage per RECIST at any evaluation&#xD;
        timepoint) ii. Ongoing stable disease on recent scans iii. Last treatment with an&#xD;
        anti-PD-1/PD-L1 agent within 6 weeks prior to starting protocol treatment&#xD;
&#xD;
          -  Availability of stored tumor tissue OR new tumor biopsy Archival tissue for PD-L1&#xD;
             staining (alternatively a new biopsy (core) at baseline can be used). A minimum of 10&#xD;
             slides is required (unless approval from the PI is obtained)&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  Known human papillomavirus (HPV) status&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1&#xD;
&#xD;
          -  Be willing and able to provide written informed consent for the trial.&#xD;
&#xD;
          -  Aged 18 years or older&#xD;
&#xD;
          -  Demonstrate reasonable organ function&#xD;
&#xD;
          -  Women of childbearing potential should have a negative urine or serum pregnancy test&#xD;
&#xD;
          -  Women of childbearing potential should be willing to use 2 methods of birth control or&#xD;
             be surgically sterile, or abstain from heterosexual activity for the course of the&#xD;
             study through 120 days after the last dose of study medication&#xD;
&#xD;
          -  Males should agree to use an adequate method of birth control starting with the first&#xD;
             dose of study therapy through 120 days after the last dose of study medication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently participating and receiving treatment in a research study or has&#xD;
             participated in a study of an investigational therapy and received study therapy or&#xD;
             used an investigational device within 2 weeks of the first dose of treatment on this&#xD;
             study&#xD;
&#xD;
          -  Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other&#xD;
             form of immunosuppressive therapy within 7 days prior to the first dose of trial&#xD;
             treatment.&#xD;
&#xD;
          -  Known history of active TB (Bacillus Tuberculosis)&#xD;
&#xD;
          -  Hypersensitivity to pembrolizumab, epacadostat or any of its excipients.&#xD;
&#xD;
          -  Has received prior anti-cancer monoclonal antibody (mAb) within 3 weeks prior to study&#xD;
             Day 1, or targeted small molecule therapy within 2 weeks prior to study Day 1, or who&#xD;
             has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents&#xD;
             administered more than 4 weeks earlier.&#xD;
&#xD;
          -  Has not recovered from prior surgery, chemotherapy or radiation therapy from adverse&#xD;
             events due to a previous treatment/ administered agent (i.e., ≤ Grade 1 or return to&#xD;
             baseline prior to treatment).&#xD;
&#xD;
        Note: Participants with ≤ Grade 2 neuropathy, any grade hearing loss or tinnitus, or&#xD;
        typical side effects from radiotherapy are an exception to this criterion and may qualify&#xD;
        for the study.&#xD;
&#xD;
        Note: If subject received major surgery, they must have recovered adequately from the&#xD;
        toxicity and/or complications from the intervention prior to starting therapy.&#xD;
&#xD;
          -  Has a known additional malignancy that is progressing or requires active treatment.&#xD;
             Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the&#xD;
             skin that has undergone potentially curative therapy or in situ cervical cancer or any&#xD;
             tumors that are not likely to influence live expectancy in the subsequent 3 years&#xD;
             without active treatment (e.g. low grade prostate cancer in absence of therapy).&#xD;
&#xD;
          -  Has known active (=growing) central nervous system (CNS) metastases and/or&#xD;
             carcinomatous meningitis. Radiation or resected brain metastasis are acceptable if&#xD;
             clinically stable.&#xD;
&#xD;
          -  Has active autoimmune disease that has required systemic treatment in the past 2 years&#xD;
             (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive&#xD;
             drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid&#xD;
             replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a&#xD;
             form of systemic treatment.&#xD;
&#xD;
          -  Has known history of, or any evidence of active, non-infectious pneumonitis.&#xD;
&#xD;
          -  Warfarin use, even if low dose warfarin is not acceptable. However, other&#xD;
             anti-coagulants (e.g. aspirin, enoxaparin and heparin derivatives, thrombin&#xD;
             inhibitors, etc) are acceptable.&#xD;
&#xD;
          -  Has a history or current evidence of any condition, therapy, or laboratory abnormality&#xD;
             that might confound the results of the trial, interfere with the subject's&#xD;
             participation for the full duration of the trial, or is not in the best interest of&#xD;
             the subject to participate, in the opinion of the treating investigator.&#xD;
&#xD;
          -  Has known psychiatric or substance abuse disorders that would interfere with&#xD;
             cooperation with the requirements of the trial.&#xD;
&#xD;
          -  Is pregnant or breastfeeding, or expecting to conceive or father children within the&#xD;
             projected duration of the trial, starting with the pre-screening or screening visit&#xD;
             through 120 days after the last dose of trial treatment.&#xD;
&#xD;
          -  Has received prior therapy with an IDO inhibiting agent.&#xD;
&#xD;
          -  Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).&#xD;
&#xD;
          -  Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA&#xD;
             [qualitative] is detected).&#xD;
&#xD;
          -  Has received a live vaccine within 30 days of planned start of study therapy.&#xD;
&#xD;
          -  Has received MAO-inhibitors (MAOI) or drug which has significant MAOI activity&#xD;
             (meperidine, linezolid, methylene blue) within the 21 days before screening.&#xD;
&#xD;
          -  History of Serotonin Syndrome after receiving serotonergic drugs.&#xD;
&#xD;
          -  History or presence of an abnormal electrocardiogram (ECG) that, in the investigator's&#xD;
             opinion, is clinically meaningful. Screening QTc interval &gt; 470 milliseconds is&#xD;
             excluded.&#xD;
&#xD;
          -  Use of any UGT1A9 inhibitor from screening through follow-up period, including the&#xD;
             following: diclofenac, imipramine, ketoconazole, mefenamic acid, and probenecid. See&#xD;
             Section 5.11 for more details.&#xD;
&#xD;
          -  History of organ transplant that requires use of immunosuppressives.&#xD;
&#xD;
          -  Any condition that would jeopardize the safety of the subject or compliance with the&#xD;
             Protocol.&#xD;
&#xD;
          -  Clinically significant cardiac disease, including unstable angina, acute myocardial&#xD;
             infarction within 6 months from Day 1 of study drug administration, New York Heart&#xD;
             Association Class III or IV congestive heart failure, and arrhythmia requiring therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tanguy Seiwert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>March 6, 2018</study_first_submitted>
  <study_first_submitted_qc>March 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2018</study_first_posted>
  <results_first_submitted>January 3, 2020</results_first_submitted>
  <results_first_submitted_qc>January 3, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 27, 2020</results_first_posted>
  <last_update_submitted>January 3, 2020</last_update_submitted>
  <last_update_submitted_qc>January 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 24, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT03463161/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Acquired Resistance or Suboptimal Benefit Group</title>
          <description>Participants that have or have not benefited from prior treatment with immunotherapy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Acquired Resistance or Suboptimal Benefit Group</title>
          <description>Participants that have or have not benefited from prior treatment with immunotherapy.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.5" lower_limit="52" upper_limit="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Rate</title>
        <description>Rate of clinical disease response (tumor shrinkage) as seen on imaging.</description>
        <time_frame>up to 18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acquired Resistance or Suboptimal Benefit Group</title>
            <description>Participants that have or have not benefited from prior treatment with immunotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate</title>
          <description>Rate of clinical disease response (tumor shrinkage) as seen on imaging.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival</title>
        <description>Number of patients that have not had disease worsening across both study groups.</description>
        <time_frame>1 year</time_frame>
        <population>Study terminated after two patients were enrolled due to conflict of interest with no further patient follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Acquired Resistance or Suboptimal Benefit Group</title>
            <description>Participants that have or have not benefited from prior treatment with immunotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival</title>
          <description>Number of patients that have not had disease worsening across both study groups.</description>
          <population>Study terminated after two patients were enrolled due to conflict of interest with no further patient follow-up.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Number of patients surviving across both study groups.</description>
        <time_frame>1 year</time_frame>
        <population>Study terminated after two patients were enrolled due to conflict of interest with no further patient follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Acquired Resistance or Suboptimal Benefit Group</title>
            <description>Participants that have or have not benefited from prior treatment with immunotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Number of patients surviving across both study groups.</description>
          <population>Study terminated after two patients were enrolled due to conflict of interest with no further patient follow-up.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effects</title>
        <description>Number of patients with side effect. Summary of side effects by type is provided in adverse events section below.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acquired Resistance or Suboptimal Benefit Group</title>
            <description>Participants that have or have not benefited from prior treatment with immunotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effects</title>
          <description>Number of patients with side effect. Summary of side effects by type is provided in adverse events section below.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Acquired Resistance or Suboptimal Benefit Group</title>
          <description>Participants that have or have not benefited from prior treatment with immunotherapy.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>GastGastrointestinal disorders - Other, specifyrointestinal disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Theodore Karrison, PhD</name_or_title>
      <organization>University of Chicago</organization>
      <phone>(773) 702-9326</phone>
      <email>tkarrison@health.bsd.uchicago.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

